Cargando…
Differential Effects of Genistein on Prostate Cancer Cells Depend on Mutational Status of the Androgen Receptor
Blocking the androgen receptor (AR) activity is the main goal of therapies for advanced prostate cancer (PCa). However, relapse with a more aggressive, hormone refractory PCa arises, which harbors restored AR activity. One mechanism of such reactivation occurs through acquisition of AR mutations tha...
Autores principales: | Mahmoud, Abeer M., Zhu, Tian, Parray, Aijaz, Siddique, Hifzur R., Yang, Wancai, Saleem, Mohammad, Bosland, Maarten C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805529/ https://www.ncbi.nlm.nih.gov/pubmed/24167630 http://dx.doi.org/10.1371/journal.pone.0078479 |
Ejemplares similares
-
Hormones and prostate carcinogenesis: Androgens and estrogens
por: Bosland, Maarten C., et al.
Publicado: (2011) -
Castration-resistant prostate cancer: potential targets and therapies
por: Parray, Aijaz, et al.
Publicado: (2012) -
BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer
por: Siddique, Hifzur Rahman, et al.
Publicado: (2013) -
Correction: BMI1, Stem Cell Factor Acting as Novel Serum-biomarker for Caucasian and African-American Prostate Cancer
por: Siddique, Hifzur Rahman, et al.
Publicado: (2013) -
BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 Signaling
por: Siddique, Hifzur Rahman, et al.
Publicado: (2013)